National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Availability of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Test Method Evaluation Report: In Vitro, 15757-15758 [E8-5936]

Download as PDF Federal Register / Vol. 73, No. 58 / Tuesday, March 25, 2008 / Notices bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/. Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 9, 2008. A. Federal Reserve Bank of Chicago (Burl Thornton, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414: 1. First Fontanelle Employee Stock Ownership Plan and Trust, Fontanelle, Iowa; to indirectly engage in insurance agency activities through Corn Belt Insurance Agency, Massena, Iowa, and thereby indirectly acquire First Fontanelle Bancorporation, Fontanelle, Iowa pursuant to section 225.28(b)(11)(iii)(A) of Regulation Y. Board of Governors of the Federal Reserve System, March 20, 2008. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc.E8–5970 Filed 3–24–08; 8:45 am] BILLING CODE 6210–01–S mstockstill on PROD1PC66 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Availability of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Test Method Evaluation Report: In Vitro Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral Systemic Toxicity Tests and the Final Background Review Document for In Vitro Cytotoxicity Test Methods for Estimating Acute Oral Systemic Toxicity; Notice of Transmittal of ICCVAM Test Method Recommendations to Federal Agencies National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). AGENCY: VerDate Aug<31>2005 18:33 Mar 24, 2008 Jkt 214001 Availability of ICCVAM Test Method Evaluation Report and Final Background Review Document. ACTION: SUMMARY: NICEATM announces availability of the ICCVAM Test Method Evaluation Report: In Vitro Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral Systemic Toxicity Tests (NIH Publication 07–4519). The report describes two in vitro basal cytotoxicity neutral red uptake (NRU) test methods that can be used for estimating starting doses for acute oral toxicity tests. The report includes ICCVAM’s (a) final test method recommendations on the use of these two test methods, (b) recommended test method protocols for future use, (c) recommendations for future studies to further characterize the usefulness and limitations of in vitro methods for assessing acute systemic toxicity, and (d) recommended performance standards for tests with similar scientific principles and that measure or predict acute oral systemic toxicity. The report recommends the use of these methods in a weight-of-evidence approach to determine starting doses for acute oral systemic toxicity tests with rodents. The report also recommends that these in vitro test methods be considered before using animals for acute oral systemic toxicity testing and used when determined appropriate. NICEATM also announces the availability of the final Background Review Document: In Vitro Cytotoxicity Test Methods for Estimating Acute Oral Systemic Toxicity (BRD) (NIH Publication 07–4518). The BRD provides data and analyses from a collaborative international validation study organized by NICEATM and the European Centre for the Validation of Alternative Methods (ECVAM) to evaluate the usefulness and limitations of two in vitro basal cytotoxicity NRU test methods using either BALB/c 3T3 mouse fibroblasts (3T3) or primary human epidermal keratinocytes (NHK) for estimating acute oral rodent toxicity. Electronic copies of the ICCVAM Test Method Evaluation Report and the BRD are available from the ICCVAM/ NICEATM Web site at https:// iccvam.niehs.nih.gov or by contacting NICEATM (see FOR FURTHER INFORMATION CONTACT). The ICCVAM Test Method Evaluation Report and the final BRD have been forwarded to U.S. Federal agencies for regulatory and other acceptance considerations where applicable. Responses will be posted on the ICCVAM/NICEATM Web site as they are received. FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director, NICEATM, PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 15757 NIEHS, P.O. Box 12233, MD EC–17, Research Triangle Park, NC 27709, (phone) 919–541–2384, (fax) 919–541– 0947, (e-mail) niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, 79 T.W. Alexander Drive, Building 4401, Room 3128, Research Triangle Park, NC 27709. SUPPLEMENTARY INFORMATION: Background In 2002, NICEATM and ECVAM initiated a collaborative, international, multi-laboratory validation study to independently evaluate the usefulness of the 3T3 and NHK NRU basal cytotoxicity test methods for estimating acute oral rodent toxicity and for estimating starting doses for in vivo rodent acute oral toxicity tests. The 3T3 and NHK NRU test methods were evaluated with 72 reference substances. Once the study was completed in January 2005, NICEATM prepared a draft BRD that contained comprehensive summaries of the data generated in the validation study, analyses of the relevance and reliability of the two test methods, and simulation analyses of the refinement (i.e., to lessen or avoid pain and distress) and reduction in animal use that might occur if these tests were used as adjuncts to two acute oral toxicity test methods (i.e., the Up-andDown Procedure and the Acute Toxic Class method). The draft BRD was released for public comment on March 21, 2006 (Federal Register, Vol. 71, No. 54, pp. 14229–14231). On May 23, 2006, NICEATM, on behalf of ICCVAM, convened an independent, scientific peer review panel meeting to review the draft BRD and evaluate the validation status of the 3T3 and NHK NRU test methods for determining starting doses for in vivo acute oral systemic toxicity tests. The peer review panel’s report was released in July 2006 (Federal Register, Vol. 71, No. 132, pp. 39122–39123). At a public teleconference meeting on August 3, 2006 (Federal Register, Vol. 71, No. 132, pp. 39121–39122), the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) reviewed and endorsed the conclusions of the peer review panel (minutes from the teleconference are available at https://ntp.niehs.nih.gov/files/ SACATMAug06MinutesVF081506.pdf). ICCVAM considered the peer panel report, public comments, SACATM comments, and the draft BRD in finalizing its recommendations on the use of these two in vitro basal cytotoxicity test methods for estimating starting doses for acute oral systemic toxicity tests. The ICCVAM Test Method Evaluation Report includes the ICCVAM E:\FR\FM\25MRN1.SGM 25MRN1 15758 Federal Register / Vol. 73, No. 58 / Tuesday, March 25, 2008 / Notices recommendations on the use of the two in vitro NRU test methods, as well as recommended test method protocols, recommendations for future studies to further characterize the usefulness and limitations of in vitro methods for assessing acute systemic toxicity, recommended performance standards for tests with similar scientific principles and that measure or predict acute oral systemic toxicity, the peer panel report and Federal Register notices. The final BRD, which provides the supporting documentation for this report, is available as a separate document. The ICCVAM Test Method Evaluation Report and the supporting final BRD were forwarded to U.S. Federal agencies for their consideration for regulatory acceptance as required by the ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3). Agencies’ responses to the test method recommendations will be posted on the ICCVAM/ NICEATM Web site as they are received. Background Information on ICCVAM, NICEATM, and SACATM ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that use, generate, or disseminate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability and promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety and hazards of chemicals and products and that refine, reduce, and replace animal use. The ICCVAM Authorization Act of 2000 established ICCVAM as a permanent interagency committee of the NIEHS under NICEATM. NICEATM administers ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of U.S. Federal agencies. Additional information about ICCVAM and NICEATM can be found on their Web site (https://iccvam.niehs.nih.gov). SACATM was established January 9, 2002, and is composed of scientists from the public and private sectors (Federal Register, Vol. 67, No. 49, page 11358). SACATM provides advice to the Director of the NIEHS, to ICCVAM, and to NICEATM regarding the statutorily mandated duties of ICCVAM and activities of NICEATM. Additional information about SACATM, including the charter, roster, and records of past meetings, can be found at https:// ntp.niehs.nih.gov/ see ‘‘Advisory Board & Committees’’ (or directly at https:// ntp.niehs.nih.gov/go/167). Dated: March 14, 2008. Samuel H. Wilson, Acting Director, National Institute of Environmental Health Sciences and National Toxicology Program. [FR Doc. E8–5936 Filed 3–24–08; 8:45 am] FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ confidentiality/. SUPPLEMENTARY INFORMATION: The Workgroup Members will continue discussing and evaluating the confidentiality, privacy, and security protections and requirements for participants in electronic health information exchange environments. The meeting will be available via Web cast. For additional information, go to: https://www.hhs.gov/healthit/ahic/ cps_instruct.html. Dated: March 13, 2008. Judith Sparrow, Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology. [FR Doc. E8–5853 Filed 3–24–08; 8:45 am] BILLING CODE 4150–45–M BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator for Health Information Technology; American Health Information Community Confidentiality, Privacy, & Security Workgroup Meeting ACTION: Announcement of meeting. SUMMARY: This notice announces the 18th meeting of the American Health Information Community Confidentiality, Privacy, & Security Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App.) DATES: April 17, 2008, from 1 p.m. to 5 p.m. (Eastern Time). ADDRESSES: Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090 (please bring photo ID for entry to a Federal building). Administration for Children and Families Proposed Information Collection Activity; Comment Request Proposed Projects Title: Grants to States for Access and Visitation: State Child Access Program Survey. OMB No.: 0970–0204. Description: On an annual basis, States must provide OCSE with data on programs that the Grants to States for Access and Visitation Program has funded. These program reporting requirements include, but are not limited to, the collection of data on the number of parents served, types of services delivered, program outcomes, client socio-economic data, referral sources, and other relevant data. OCSE is proposing revisions to the current survey. ANNUAL BURDEN ESTIMATES No. of respondents No. of responses per respondent Average burden hours per response Total burden hours State Child Access Program Survey ................................................................ mstockstill on PROD1PC66 with NOTICES Instrument 314 1 15 4,710 Estimated Total Annual Burden Hours: 4,710. In compliance with the requirements of Section 506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and VerDate Aug<31>2005 18:33 Mar 24, 2008 Jkt 214001 Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: Office of Administration, Office of Information E:\FR\FM\25MRN1.SGM 25MRN1

Agencies

[Federal Register Volume 73, Number 58 (Tuesday, March 25, 2008)]
[Notices]
[Pages 15757-15758]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-5936]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Toxicology Program (NTP); NTP Interagency Center for the 
Evaluation of Alternative Toxicological Methods (NICEATM); Availability 
of the Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM) Test Method Evaluation Report: In Vitro 
Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral 
Systemic Toxicity Tests and the Final Background Review Document for In 
Vitro Cytotoxicity Test Methods for Estimating Acute Oral Systemic 
Toxicity; Notice of Transmittal of ICCVAM Test Method Recommendations 
to Federal Agencies

AGENCY: National Institute of Environmental Health Sciences (NIEHS), 
National Institutes of Health (NIH).

ACTION: Availability of ICCVAM Test Method Evaluation Report and Final 
Background Review Document.

-----------------------------------------------------------------------

SUMMARY: NICEATM announces availability of the ICCVAM Test Method 
Evaluation Report: In Vitro Cytotoxicity Test Methods for Estimating 
Starting Doses for Acute Oral Systemic Toxicity Tests (NIH Publication 
07-4519). The report describes two in vitro basal cytotoxicity neutral 
red uptake (NRU) test methods that can be used for estimating starting 
doses for acute oral toxicity tests. The report includes ICCVAM's (a) 
final test method recommendations on the use of these two test methods, 
(b) recommended test method protocols for future use, (c) 
recommendations for future studies to further characterize the 
usefulness and limitations of in vitro methods for assessing acute 
systemic toxicity, and (d) recommended performance standards for tests 
with similar scientific principles and that measure or predict acute 
oral systemic toxicity. The report recommends the use of these methods 
in a weight-of-evidence approach to determine starting doses for acute 
oral systemic toxicity tests with rodents. The report also recommends 
that these in vitro test methods be considered before using animals for 
acute oral systemic toxicity testing and used when determined 
appropriate.
    NICEATM also announces the availability of the final Background 
Review Document: In Vitro Cytotoxicity Test Methods for Estimating 
Acute Oral Systemic Toxicity (BRD) (NIH Publication 07-4518). The BRD 
provides data and analyses from a collaborative international 
validation study organized by NICEATM and the European Centre for the 
Validation of Alternative Methods (ECVAM) to evaluate the usefulness 
and limitations of two in vitro basal cytotoxicity NRU test methods 
using either BALB/c 3T3 mouse fibroblasts (3T3) or primary human 
epidermal keratinocytes (NHK) for estimating acute oral rodent 
toxicity.
    Electronic copies of the ICCVAM Test Method Evaluation Report and 
the BRD are available from the ICCVAM/NICEATM Web site at https://
iccvam.niehs.nih.gov or by contacting NICEATM (see FOR FURTHER 
INFORMATION CONTACT). The ICCVAM Test Method Evaluation Report and the 
final BRD have been forwarded to U.S. Federal agencies for regulatory 
and other acceptance considerations where applicable. Responses will be 
posted on the ICCVAM/NICEATM Web site as they are received.

FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director, 
NICEATM, NIEHS, P.O. Box 12233, MD EC-17, Research Triangle Park, NC 
27709, (phone) 919-541-2384, (fax) 919-541-0947, (e-mail) 
niceatm@niehs.nih.gov. Courier address: NICEATM, NIEHS, 79 T.W. 
Alexander Drive, Building 4401, Room 3128, Research Triangle Park, NC 
27709.

SUPPLEMENTARY INFORMATION: 

Background

    In 2002, NICEATM and ECVAM initiated a collaborative, 
international, multi-laboratory validation study to independently 
evaluate the usefulness of the 3T3 and NHK NRU basal cytotoxicity test 
methods for estimating acute oral rodent toxicity and for estimating 
starting doses for in vivo rodent acute oral toxicity tests. The 3T3 
and NHK NRU test methods were evaluated with 72 reference substances. 
Once the study was completed in January 2005, NICEATM prepared a draft 
BRD that contained comprehensive summaries of the data generated in the 
validation study, analyses of the relevance and reliability of the two 
test methods, and simulation analyses of the refinement (i.e., to 
lessen or avoid pain and distress) and reduction in animal use that 
might occur if these tests were used as adjuncts to two acute oral 
toxicity test methods (i.e., the Up-and-Down Procedure and the Acute 
Toxic Class method). The draft BRD was released for public comment on 
March 21, 2006 (Federal Register, Vol. 71, No. 54, pp. 14229-14231).
    On May 23, 2006, NICEATM, on behalf of ICCVAM, convened an 
independent, scientific peer review panel meeting to review the draft 
BRD and evaluate the validation status of the 3T3 and NHK NRU test 
methods for determining starting doses for in vivo acute oral systemic 
toxicity tests. The peer review panel's report was released in July 
2006 (Federal Register, Vol. 71, No. 132, pp. 39122-39123). At a public 
teleconference meeting on August 3, 2006 (Federal Register, Vol. 71, 
No. 132, pp. 39121-39122), the Scientific Advisory Committee on 
Alternative Toxicological Methods (SACATM) reviewed and endorsed the 
conclusions of the peer review panel (minutes from the teleconference 
are available at https://ntp.niehs.nih.gov/files/
SACATMAug06MinutesVF081506.pdf).
    ICCVAM considered the peer panel report, public comments, SACATM 
comments, and the draft BRD in finalizing its recommendations on the 
use of these two in vitro basal cytotoxicity test methods for 
estimating starting doses for acute oral systemic toxicity tests. The 
ICCVAM Test Method Evaluation Report includes the ICCVAM

[[Page 15758]]

recommendations on the use of the two in vitro NRU test methods, as 
well as recommended test method protocols, recommendations for future 
studies to further characterize the usefulness and limitations of in 
vitro methods for assessing acute systemic toxicity, recommended 
performance standards for tests with similar scientific principles and 
that measure or predict acute oral systemic toxicity, the peer panel 
report and Federal Register notices. The final BRD, which provides the 
supporting documentation for this report, is available as a separate 
document. The ICCVAM Test Method Evaluation Report and the supporting 
final BRD were forwarded to U.S. Federal agencies for their 
consideration for regulatory acceptance as required by the ICCVAM 
Authorization Act of 2000 (42 U.S.C. 285l-3). Agencies' responses to 
the test method recommendations will be posted on the ICCVAM/NICEATM 
Web site as they are received.

Background Information on ICCVAM, NICEATM, and SACATM

    ICCVAM is an interagency committee composed of representatives from 
15 Federal regulatory and research agencies that use, generate, or 
disseminate toxicological information. ICCVAM conducts technical 
evaluations of new, revised, and alternative methods with regulatory 
applicability and promotes the scientific validation and regulatory 
acceptance of toxicological test methods that more accurately assess 
the safety and hazards of chemicals and products and that refine, 
reduce, and replace animal use. The ICCVAM Authorization Act of 2000 
established ICCVAM as a permanent interagency committee of the NIEHS 
under NICEATM. NICEATM administers ICCVAM and provides scientific and 
operational support for ICCVAM-related activities. NICEATM and ICCVAM 
work collaboratively to evaluate new and improved test methods 
applicable to the needs of U.S. Federal agencies. Additional 
information about ICCVAM and NICEATM can be found on their Web site 
(https://iccvam.niehs.nih.gov).
    SACATM was established January 9, 2002, and is composed of 
scientists from the public and private sectors (Federal Register, Vol. 
67, No. 49, page 11358). SACATM provides advice to the Director of the 
NIEHS, to ICCVAM, and to NICEATM regarding the statutorily mandated 
duties of ICCVAM and activities of NICEATM. Additional information 
about SACATM, including the charter, roster, and records of past 
meetings, can be found at https://ntp.niehs.nih.gov/ see ``Advisory 
Board & Committees'' (or directly at https://ntp.niehs.nih.gov/go/167).

    Dated: March 14, 2008.
Samuel H. Wilson,
Acting Director, National Institute of Environmental Health Sciences 
and National Toxicology Program.
 [FR Doc. E8-5936 Filed 3-24-08; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.